Skip to content
10-Q

Quarterly Report

INOZYME PHARMA, INC.

0000950170-25-070921

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 64.56M sh
Shares Diluted Q1 2025 · Mar 31, 2025 64.28M sh
Shares Diluted Q1 2025 · Mar 31, 2024 61.77M sh
Capex Q1 2025 · Mar 31, 2025 $0
Capex Q1 2025 · Mar 31, 2024 $32K
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$29.15M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$24.53M
Long Term Debt Q1 2025 · Mar 31, 2025 $20.59M
Long Term Debt Q1 2025 · Dec 31, 2024 $31.46M
Short Term Debt Q1 2025 · Mar 31, 2025 $25.7M
Short Term Investments Q1 2025 · Mar 31, 2025 $58.93M
Short Term Investments Q1 2025 · Dec 31, 2024 $92.01M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $25.85M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $21.08M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $20.62M
Stockholders Equity Q1 2025 · Mar 31, 2025 $31.8M
Stockholders Equity Q1 2025 · Dec 31, 2024 $57.83M
Stockholders Equity Q1 2025 · Mar 31, 2024 $118.84M
Stockholders Equity Q1 2025 · Dec 31, 2023 $140.48M
Current Liabilities Q1 2025 · Mar 31, 2025 $42.78M
Current Liabilities Q1 2025 · Dec 31, 2024 $33.9M
Total Liabilities Q1 2025 · Mar 31, 2025 $63.37M
Total Liabilities Q1 2025 · Dec 31, 2024 $65.36M
Current Assets Q1 2025 · Mar 31, 2025 $93.64M
Current Assets Q1 2025 · Dec 31, 2024 $120.68M
Total Assets Q1 2025 · Mar 31, 2025 $95.16M
Total Assets Q1 2025 · Dec 31, 2024 $123.18M
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.44
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.38
Eps Basic Q1 2025 · Mar 31, 2025 −$0.44
Eps Basic Q1 2025 · Mar 31, 2024 −$0.38
Sga Expense Q1 2025 · Mar 31, 2025 $5.41M
Sga Expense Q1 2025 · Mar 31, 2024 $5.23M
Rd Expense Q1 2025 · Mar 31, 2025 $20.38M
Rd Expense Q1 2025 · Mar 31, 2024 $19.11M
Net Income Q1 2025 · Mar 31, 2025 −$28.04M
Net Income Q1 2025 · Mar 31, 2024 −$23.35M
Operating Income Q1 2025 · Mar 31, 2025 −$27.69M
Operating Income Q1 2025 · Mar 31, 2024 −$24.35M